# EDGAR Filing Document

**Accession Number:** 0001740279
**File Stem:** 0001193125-26-022614
**Filing Date:** 2026-1
**Character Count:** 2654
**Document Hash:** 7718ed995fba31232864f1a7f9887a83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-022614.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0001193125-26-022614

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510

**IN8bio, Inc.** 

**350 5th Avenue, Suite 5330** 

**New York, New York 10118** 

January 26, 2026

**<u>VIA EDGAR</u>**

Division of Corporation Finance

Office of Technology

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **RE:** | **IN8bio, Inc.**  |

---

**Registration Statement on Form S-3** 

**File No. 333-292830** 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, IN8bio, Inc. (the "**Registrant**") hereby requests that the U.S. Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on January 28, 2026, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Jaime L. Chase and Trey Reilly of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Jaime L. Chase at (202) 728-7096 or, in her absence, Trey Reilly of Cooley LLP, counsel to the Registrant, at (212) 479-6502.

---

| | |
|:---|:---|
|  Very truly yours, | Very truly yours, |
|  **IN8BIO, INC.** | **IN8BIO, INC.** |
|  By: | /s/ Patrick McCall |
|  Name: | Patrick McCall |
|  Title: | Chief Financial Officer |

---

cc: William Ho, IN8bio, Inc.

Jaime L. Chase, Cooley LLP

Trey Reilly, Cooley LLP